Valneva (NASDAQ:VALN) Stock Price Up 6.3%

Valneva SE (NASDAQ:VALN – Get Rating)’s share price was up 6.3% during mid-day trading on Monday . The company traded as high as $15.96 and last traded at $15.96. Approximately 1,241 shares changed hands during mid-day trading, a decline of 66% from the average daily volume of 3,617 shares. The stock had previously closed at $15.02.

Analysts Set New Price Targets

Separately, HC Wainwright decreased their target price on shares of Valneva from $27.00 to $25.00 in a research report on Monday, December 5th.

Valneva Stock Down 1.8 %

The company has a debt-to-equity ratio of 0.57, a current ratio of 1.27 and a quick ratio of 1.02. The company’s 50-day moving average is $13.96 and its 200 day moving average is $15.38.

Valneva (NASDAQ:VALN – Get Rating) last posted its quarterly earnings data on Thursday, November 10th. The company reported $1.33 EPS for the quarter, topping the consensus estimate of ($0.14) by $1.47. The company had revenue of $157.92 million for the quarter, compared to analyst estimates of $78.52 million. Analysts expect that Valneva SE will post -1.19 EPS for the current fiscal year.

Institutional Investors Weigh In On Valneva

Institutional investors and hedge funds have recently modified their holdings of the company. General American Investors Co. Inc. acquired a new stake in Valneva during the 3rd quarter valued at approximately $3,768,000. UBS Group AG purchased a new stake in Valneva in the second quarter valued at $31,000. Bank of America Corp DE acquired a new stake in Valneva during the 1st quarter worth about $858,000. Finally, Jane Street Group LLC raised its stake in shares of Valneva by 85.9% during the 1st quarter. Jane Street Group LLC now owns 16,584 shares of the company’s stock valued at $569,000 after buying an additional 7,664 shares during the last quarter. Institutional investors and hedge funds own 15.83% of the company’s stock.

About Valneva

(Get Rating)

Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2.